JAML and cancer: Besides, researchers have proved that treatment with anti-AMICA1 antibodies or AMICA1 knockdown can reduce the effectiveness of dendritic cell-based cancer immunotherapy, which means that AMICA1 may function as a potential novel immunotherapy target.